Hisamitsu Pharmaceutical revises outlook: what it means for Hisamitsu Pharmaceutical stock

Published on 10/02/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eight analysts rate Hisamitsu Pharmaceutical stock, with 4 sells and 4 holds. The average target is JPY 4,335 versus JPY 5,903.37.

Hisamitsu, JP3784600003, Illustration mit AI erstellt.

Hisamitsu Pharmaceutical (JP3784600003) generated JPY 156.01 billion in revenue in fiscal 2025, up 10.09 percent from JPY 141.71 billion in fiscal 2024, according to Eulerpool. On October 1, 2026, MINKABU reported an earnings forecast revision, making the updated outlook the latest dated company development.

October 1 outlook revision

The MINKABU notice identifies a revision to Hisamitsu Pharmaceutical's earnings forecast, but its accessible page does not reproduce the revised numerical guidance. The event still matters because the fiscal 2025 baseline shows a business with rising sales and operating profit.

Hisamitsu Pharmaceutical's fiscal 2025 EBIT reached JPY 18.90 billion, compared with JPY 13.17 billion in fiscal 2024, while net income rose to JPY 21.76 billion from JPY 13.97 billion, according to Eulerpool. The figures imply that fiscal 2025 profit growth outpaced revenue growth, giving the October outlook revision greater significance than a sales-only update.

Profit growth outpaced revenue

The historical comparison is clear: revenue increased 10.09 percent between fiscal 2024 and fiscal 2025, while EBIT climbed 43.51 percent over the same periods. Net income expanded 55.76 percent, according to Eulerpool.

That operating leverage is the key figure for interpreting the revised outlook. It suggests that margin and earnings delivery, rather than revenue growth alone, remain central to the company's valuation narrative.

Analyst target below last trade

Eulerpool lists 8 analyst ratings, including 4 hold ratings and 4 sell ratings, with an average 12-month target of JPY 4,335.00 against a last traded price of JPY 5,903.37. The target is therefore JPY 1,568.37 below the last traded price, according to Eulerpool.

The company also moved through a major ownership and listing transition. Its investor-relations page lists an announcement dated May 8, 2026, concerning the delisting of its shares, while the same page records the fiscal year ended February 2026 fourth-quarter results on April 13, 2026, according to Hisamitsu Pharmaceutical.

Market value on September 16

Hisamitsu Pharmaceutical had a market capitalization of JPY 435.2 billion as of September 16, 2026. The reported 52-week range was JPY 3,931.00 to JPY 6,510.00, placing the last traded price of JPY 5,903.37 below the yearly high and above the yearly low.